Lars Fruergaard Jørgensen resigns as CEO of Novo Nordisk. Discover the implications of this leadership change for the pharmaceutical industry.
In a surprising move, Lars Fruergaard Jørgensen is stepping down as CEO of Novo Nordisk after years of leading the company through a successful phase in obesity and diabetes medications. As the search for his successor begins, what does this mean for the future of the pharmaceutical giant?